Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Decreases By 12.6%

BioCardia, Inc. (NASDAQ:BCDA) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 132,100 shares, a drop of 12.6% from the September 15th total of 151,200 shares. Based on an average daily volume of 832,300 shares, the short-interest ratio is presently 0.2 days. Currently, 4.8% of the company’s shares are sold short.

BioCardia Stock Down 5.8 %

Shares of NASDAQ:BCDA opened at $2.44 on Wednesday. The business has a fifty day simple moving average of $2.78 and a 200-day simple moving average of $3.83. BioCardia has a 52 week low of $1.96 and a 52 week high of $23.25. The company has a market cap of $4.44 million, a P/E ratio of -0.35 and a beta of 1.26.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.78). Sell-side analysts expect that BioCardia will post -5.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright raised their target price on shares of BioCardia from $4.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 16th.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.